{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,21]],"date-time":"2026-09-21T07:58:03Z","timestamp":1789977483645,"version":"4.0.1"},"reference-count":36,"publisher":"Spandidos Publications","issue":"1","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2017,7]]},"DOI":"10.3892\/ol.2017.6106","type":"journal-article","created":{"date-parts":[[2017,4,28]],"date-time":"2017-04-28T09:18:07Z","timestamp":1493371087000},"page":"10-14","source":"Crossref","is-referenced-by-count":3,"title":["Pediatric haematopoiesis and related malignancies"],"prefix":"10.3892","volume":"14","author":[{"given":"Mingwei","family":"Jin","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shumei","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qi","family":"An","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"2249","published-online":{"date-parts":[[2017,4,28]]},"reference":[{"key":"key20180108115558_b1-ol-0-0-6106","doi-asserted-by":"crossref","first-page":"e1601602","DOI":"10.1126\/sciadv.1601602","article-title":"ASXL1 interacts with the cohesin complex to maintain chromatid separation and gene expression for normal hematopoiesis","volume":"3","author":"Li","year":"2017","journal-title":"Sci Adv"},{"key":"key20180108115558_b2-ol-0-0-6106","doi-asserted-by":"crossref","first-page":"446","DOI":"10.1016\/j.arcmed.2003.06.004","article-title":"The biology of hematopoietic stem cells","volume":"34","author":"Szilvassy","year":"2003","journal-title":"Arch Med Res"},{"key":"key20180108115558_b3-ol-0-0-6106","doi-asserted-by":"crossref","first-page":"332","DOI":"10.1017\/CBO9780511977633.014","volume-title":"Childhood Leukemias","author":"Pui","year":"2012","edition":"3rd"},{"key":"key20180108115558_b4-ol-0-0-6106","doi-asserted-by":"crossref","DOI":"10.1089\/jayao.2016.0091","article-title":"Anthropometry in long-term survivors of acute lymphoblastic leukemia in childhood and adolescence","author":"Collins","year":"2017","journal-title":"J Adolesc Young Adult Oncol"},{"key":"key20180108115558_b5-ol-0-0-6106","doi-asserted-by":"crossref","first-page":"3330","DOI":"10.1182\/blood.V89.9.3330","article-title":"Prognostic value of metaphase-fluorescence in situ hybridization in follow-up of patients with acute myeloid leukemia in remission","volume":"89","author":"El-Rifai","year":"1997","journal-title":"Blood"},{"key":"key20180108115558_b6-ol-0-0-6106","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1017\/CBO9780511977633.003","volume-title":"Childhood Leukemias","author":"Onciu","year":"2012","edition":"3rd"},{"key":"key20180108115558_b7-ol-0-0-6106","doi-asserted-by":"crossref","first-page":"E359","DOI":"10.1002\/ijc.29210","article-title":"Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012","volume":"136","author":"Ferlay","year":"2015","journal-title":"Int J Cancer"},{"key":"key20180108115558_b8-ol-0-0-6106","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1097\/MOP.0b013e32835c1cbe","article-title":"Global challenges in pediatric oncology","volume":"25","author":"Rodriguez-Galindo","year":"2013","journal-title":"Curr Opin Pediatr"},{"key":"key20180108115558_b9-ol-0-0-6106","doi-asserted-by":"crossref","first-page":"790","DOI":"10.1016\/S1470-2045(12)70211-5","article-title":"Global cancer transitions according to the Human Development Index (2008\u20132030): a population-based study","volume":"13","author":"Bray","year":"2012","journal-title":"Lancet Oncol"},{"key":"key20180108115558_b10-ol-0-0-6106","doi-asserted-by":"crossref","first-page":"562","DOI":"10.1002\/cncr.23220","article-title":"Significance of age in acute myeloid leukemia patients younger than 30 years: a common analysis of the pediatric trials AML-BFM 93\/98 and the adult trials AMLCG 92\/99 and AMLSG HD93\/98A","volume":"112","author":"Creutzig","year":"2008","journal-title":"Cancer"},{"key":"key20180108115558_b11-ol-0-0-6106","doi-asserted-by":"crossref","first-page":"2099","DOI":"10.1002\/cncr.22233","article-title":"Acute myeloid leukemia: epidemiology and etiology","volume":"107","author":"Deschler","year":"2006","journal-title":"Cancer"},{"key":"key20180108115558_b12-ol-0-0-6106","doi-asserted-by":"crossref","first-page":"1030","DOI":"10.1016\/S0140-6736(08)60457-2","article-title":"Acute lymphoblastic leukaemia","volume":"371","author":"Pui","year":"2008","journal-title":"Lancet"},{"key":"key20180108115558_b13-ol-0-0-6106","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1053\/j.seminhematol.2008.09.011","article-title":"Acute lymphoblastic leukemia: introduction","volume":"46","author":"Pui","year":"2009","journal-title":"Semin Hematol"},{"key":"key20180108115558_b14-ol-0-0-6106","doi-asserted-by":"crossref","first-page":"551","DOI":"10.1200\/JCO.2010.30.7405","article-title":"Biology, risk stratification, and therapy of pediatric acute leukemias: an update","volume":"29","author":"Pui","year":"2011","journal-title":"J Clin Oncol"},{"key":"key20180108115558_b15-ol-0-0-6106","doi-asserted-by":"crossref","first-page":"1165","DOI":"10.1182\/blood-2012-05-378943","article-title":"Pediatric acute lymphoblastic leukemia: where are we going and how do we get there?","volume":"120","author":"Pui","year":"2012","journal-title":"Blood"},{"key":"key20180108115558_b16-ol-0-0-6106","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1046\/j.1365-2141.1998.00574.x","article-title":"Minimal residual disease analysis for the prediction of relapse in children with standard-risk acute lymphoblastic leukaemia","volume":"100","author":"Goulden","year":"1998","journal-title":"Br J Haematol"},{"key":"key20180108115558_b17-ol-0-0-6106","doi-asserted-by":"crossref","first-page":"957","DOI":"10.1016\/S1470-2045(09)70228-1","article-title":"Dutch Childhood Oncology Group: Dexamethasone-based therapy for childhood acute lymphoblastic leukaemia: results of the prospective Dutch Childhood Oncology Group (DCOG) protocol ALL-9 (1997\u20132004)","volume":"10","author":"Veerman","year":"2009","journal-title":"Lancet Oncol"},{"key":"key20180108115558_b18-ol-0-0-6106","doi-asserted-by":"crossref","first-page":"1371","DOI":"10.1056\/NEJMoa1110169","article-title":"Outcomes after induction failure in childhood acute lymphoblastic leukemia","volume":"366","author":"Schrappe","year":"2012","journal-title":"N Engl J Med"},{"key":"key20180108115558_b19-ol-0-0-6106","doi-asserted-by":"crossref","first-page":"635","DOI":"10.1016\/S0140-6736(05)66998-X","article-title":"Chemotherapy versus allogeneic transplantation for very-high-risk childhood acute lymphoblastic leukaemia in first complete remission: comparison by genetic randomisation in an international prospective study","volume":"366","author":"Balduzzi","year":"2005","journal-title":"Lancet"},{"key":"key20180108115558_b20-ol-0-0-6106","doi-asserted-by":"crossref","first-page":"1645","DOI":"10.1002\/cncr.22102","article-title":"Adolescents and young adults with cancer: the scope of the problem and criticality of clinical trials","volume":"107","author":"Bleyer","year":"2006","journal-title":"Cancer"},{"key":"key20180108115558_b21-ol-0-0-6106","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1111\/j.1365-2141.2005.05544.x","article-title":"Clinical characteristics, biologic features and outcome for young adult patients with acute lymphoblastic leukaemia","volume":"130","author":"Nachman","year":"2005","journal-title":"Br J Haematol"},{"key":"key20180108115558_b22-ol-0-0-6106","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1038\/leu.2011.227","article-title":"ETV6-RUNX1-positive childhood acute lymphoblastic leukemia: improved outcome with contemporary therapy","volume":"26","author":"Bhojwani","year":"2012","journal-title":"Leukemia"},{"key":"key20180108115558_b23-ol-0-0-6106","doi-asserted-by":"crossref","first-page":"1045","DOI":"10.1182\/blood-2009-07-235291","article-title":"Down syndrome childhood acute lymphoblastic leukemia has a unique spectrum of sentinel cytogenetic lesions that influences treatment outcome: a report from the Childrens Oncology Group","volume":"116","author":"Maloney","year":"2010","journal-title":"Blood"},{"key":"key20180108115558_b24-ol-0-0-6106","doi-asserted-by":"crossref","first-page":"957","DOI":"10.1002\/pbc.24420","article-title":"COG Acute Lymphoblastic Leukemia Committee: Childrens Oncology Groups 2013 blueprint for research: acute lymphoblastic leukemia","volume":"60","author":"Hunger","year":"2013","journal-title":"Pediatr Blood Cancer"},{"key":"key20180108115558_b25-ol-0-0-6106","doi-asserted-by":"crossref","first-page":"5189","DOI":"10.1200\/JCO.2008.20.8959","article-title":"Young adults with acute lymphoblastic leukemia have an excellent outcome with chemotherapy alone and benefit from intensive postinduction treatment: a report from the Childrens Oncology Group","volume":"27","author":"Nachman","year":"2009","journal-title":"J Clin Oncol"},{"key":"key20180108115558_b26-ol-0-0-6106","doi-asserted-by":"crossref","first-page":"796","DOI":"10.1182\/blood.V124.21.796.796","article-title":"Favorable outcomes for older adolescents and young adults (AYA) with acute lymphoblastic leukemia (ALL): early results of US intergroup trial C10403","volume":"124","author":"Stock","year":"2014","journal-title":"Blood"},{"key":"key20180108115558_b27-ol-0-0-6106","doi-asserted-by":"crossref","first-page":"1510","DOI":"10.1182\/blood.V118.21.1510.1510","article-title":"Treatment toxicity in adolescents and young adult (AYA) patients compared with younger patients treated for high risk B-precursor acute lymphoblastic leukemia (HR-ALL): a report from the Childrens Oncology Group study AALL0232","volume":"118","author":"Larsen","year":"2011","journal-title":"Blood"},{"key":"key20180108115558_b28-ol-0-0-6106","first-page":"20","article-title":"Renewed calls for adolescents and young adults with ALL to be treated with pediatric protocols","volume":"37","author":"Carlson","year":"2015","journal-title":"Oncol Times"},{"key":"key20180108115558_b29-ol-0-0-6106","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1053\/j.seminoncol.2009.03.007","article-title":"Acute leukemia in adolescents and young adults","volume":"36","author":"Advani","year":"2009","journal-title":"Semin Oncol"},{"key":"key20180108115558_b30-ol-0-0-6106","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1007\/s11912-013-0325-5","article-title":"The adolescent and young adult with cancer: state of the art - acute leukemias","volume":"15","author":"Gramatges","year":"2013","journal-title":"Curr Oncol Rep"},{"key":"key20180108115558_b31-ol-0-0-6106","doi-asserted-by":"crossref","first-page":"2142","DOI":"10.1038\/leu.2008.251","article-title":"Factors influencing survival after relapse from acute lymphoblastic leukemia: a Childrens Oncology Group study","volume":"22","author":"Nguyen","year":"2008","journal-title":"Leukemia"},{"key":"key20180108115558_b32-ol-0-0-6106","doi-asserted-by":"crossref","first-page":"400","DOI":"10.1182\/asheducation-2015.1.400","article-title":"The use of novel monoclonal antibodies in the treatment of acute lymphoblastic leukemia","volume":"2015","author":"DeAngelo","year":"2015","journal-title":"Hematology Am Soc Hematol Educ Program"},{"key":"key20180108115558_b33-ol-0-0-6106","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1016\/S1470-2045(10)70090-5","article-title":"Minimal residual disease-directed therapy for childhood acute myeloid leukaemia: results of the AML02 multicentre trial","volume":"11","author":"Rubnitz","year":"2010","journal-title":"Lancet Oncol"},{"key":"key20180108115558_b34-ol-0-0-6106","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1142\/9789814299619_0006","volume-title":"Hematological Malignancies in Children, Adolescents and Young Adults","author":"Mullighan","year":"2012"},{"key":"key20180108115558_b35-ol-0-0-6106","doi-asserted-by":"crossref","first-page":"1425","DOI":"10.1182\/blood-2009-09-242859","article-title":"FLT3-mutant allelic burden and clinical status are predictive of response to FLT3 inhibitors in AML","volume":"115","author":"Pratz","year":"2010","journal-title":"Blood"},{"key":"key20180108115558_b36-ol-0-0-6106","doi-asserted-by":"crossref","first-page":"2489","DOI":"10.1182\/blood-2009-04-215152","article-title":"Novel prognostic subgroups in childhood 11q23\/MLL-rearranged acute myeloid leukemia: results of an international retrospective study","volume":"114","author":"Balgobind","year":"2009","journal-title":"Blood"}],"container-title":["Oncology Letters"],"original-title":[],"language":"en","deposited":{"date-parts":[[2020,10,6]],"date-time":"2020-10-06T09:46:15Z","timestamp":1601977575000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.spandidos-publications.com\/10.3892\/ol.2017.6106"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,4,28]]},"references-count":36,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2017,4,28]]},"published-print":{"date-parts":[[2017,7]]}},"alternative-id":["10.3892\/ol.2017.6106"],"URL":"https:\/\/doi.org\/10.3892\/ol.2017.6106","relation":{},"ISSN":["1792-1074","1792-1082"],"issn-type":[{"value":"1792-1074","type":"print"},{"value":"1792-1082","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,4,28]]}}}